Dr. Abasi Ene-Obong, the former CEO of 54Gene, has resurfaced as the CEO of a new company, Syndicate Bio. He went quiet after he resigned as the CEO of 54Gene about a year ago.
According to Ene-Obong in a LinkedIn post, “Today, after a few months in stealth mode, I am happy to say that we have started Syndicate Bio to empower inclusive advancements in global genomics science. Syndicate Bio is a platform biotech, driving genomics and precision medicine initiatives across the world’s most diverse regions (starting in Africa, of course!).”
“At Syndicate Bio, we use large scale partnerships with governments, pharma companies, academia, and other stakeholders to drive local precision medicine impact while creating powerful datasets that can be used for drug discovery and development,” he adds.
Syndicate Bio’s mission is to bridge the gap in global healthcare by leveraging the power of genomics and precision medicine.
Ene-Obong is joined by Jumi Popoola and Estelle Dogbo, MSc as co-founders, as well as Wubrest T. Bekele, Wissam Hamou Ph.D, and Aminu Yakubu as leaders in the company.
We expect to hear a lot more from this startup in the coming months.
1 Comment
Pingback: Nigerian biotech startup, Syndicate Bio, introduces liquid biopsy services to revolutionize cancer diagnostics in Africa - Innovation Village | Technology, Product Reviews, Business